PRJNA518030
Mus musculus Transcriptome of K-RAS-mutated lung adenocarcinoma
Lung adenocarcinomas with oncogenic K-RAS mutations exhibit activation of JAK-STAT signaling. Pharmacological inhibition of JAK signaling using ruxolitinib significantly restrains tumor progression in preclinical models of K-RAS-driven lung cancer. Ruxolitinib is an FDA-approved drug routinely use in clinics, thus our results can be straightforward evaluated in a clinical trial.